Navigation Links
Auxogyn Licenses Non-invasive Embryo Assessment Technology From Stanford University
Date:10/4/2010

MENLO PARK, Calif., Oct. 4 /PRNewswire/ -- Auxogyn, Inc., a privately held medical technology company focused on women's reproductive health, today announced that it acquired an exclusive license from Stanford University to develop a set of products that may allow medical practitioners in the field of assisted reproduction to significantly improve the effectiveness of in vitro fertilization (IVF) procedures.

The technology licensed from Stanford is described in a publication titled 'Non-invasive imaging of human embryos before embryonic genome activation predicts development to the blastocyst stage,' now appearing in the online edition of Nature Biotechnology. This landmark study demonstrated, for the first time, that human embryo fate is already determined at the four-cell stage of development. The article is authored by Professor Renee Reijo Pera, Dr. Connie Wong, Dr. Kevin Loewke, Dr. Nancy Bossert, Dr. Barry Behr, Dr. Christopher De Jonge and Dr. Thomas Baer and showed that measuring a unique set of non-invasive imaging parameters by day 2 may allow an embryologist to predict the embryos that will reach the blastocyst (day 5) stage of development with a very high degree of accuracy.

"Blastocyst formation is a critical time point in human embryo development and provides more objective criteria for selecting which embryo(s) to transfer," said Lissa Goldenstein, president and chief executive officer of Auxogyn, Inc.  "For years, researchers have searched for ways to predict the embryos most likely to reach the blastocyst stage in order to enable earlier transfer and ultimately improve live-birth rates for in vitro fertilization procedures."

"Building on the technology licensed from Stanford, we are developing a product that assesses early embryo viability at the 4-cell stage. We believe that generating key clinical data assessments may enable embryologists to improve the effectiveness of in vitro fertilization (IVF) procedures while providing women experiencing infertility the highest quality of patient care," continued Ms. Goldenstein.

About Auxogyn

Auxogyn is a privately held medical technology company focused on advancing women's reproductive health by applying its novel scientific and clinical knowledge of early human developmental biology to the field of assisted reproduction and in vitro fertilization (IVF) procedures. Auxogyn's first product in development combines a proprietary computational algorithm with developmental biology imaging capabilities to assess early embryo viability at the four-cell stage of development by identifying embryos that have the possibility of developing into a blastocyst.  Auxogyn is funded by the leading life science venture firms Kleiner Perkins Caufield & Byers, TPG Biotechnology and Merck Serono Ventures. For more information regarding Auxogyn please visit www.auxogyn.com.


'/>"/>
SOURCE Auxogyn, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Interleukin Genetics Licenses its PST(R) Genetic Test to OralDNA Labs
2. Access Pharmaceuticals Licenses MuGard to Milestone Biosciences, LLC for North America
3. MedImmune Licenses Reverse Genetics Technology to Hungarys Omninvest for Use in Influenza Vaccine Development and Production
4. Onyx Pharmaceuticals Licenses Rights to Novel Targeted Oncology Agent From BTG International
5. Stem Cell Sciences Licenses Stem Cell Technology to Leading Provider of Genetically Modified Models for Pharmaceutical Research
6. Arizona Heart Innovative Technologies Licenses New Endovascular Device
7. BioWa Licenses POTELLIGENT(R) Technology to GlaxoSmithKline for Use in Antibody Development and Commercialization
8. Artemis Health Licenses Prenatal Cell-Free DNA Analysis Technology from Stanford University
9. Implicit Licenses Clinical Stage Antibody Program From Lilly
10. Global Med Technologies(R) Licenses 90th Site in the Southeastern U.S.
11. Nanosys Licenses Nanowire Technology to QuantuMDx Group for Next Generation Diagnostic and Sequencing Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ASAE is introducing a hybrid membership model ... the option of joining or renewing through an organizational ... staff size, every employee in any size association or ... all available member benefits.   John H. ... options will allow organizations of any size and their ...
(Date:2/10/2016)... New York (PRWEB) , ... ... ... Inc. (NASDAQ: REGN) today announced that it has joined the Human Vaccines ... immunotherapies for infectious diseases and cancer. , The Human Vaccines Project ...
(Date:2/10/2016)... Wash., Feb. 10, 2016  IsoRay, Inc. (NYSE MKT: ... brachytherapy and medical radioisotope applications for the treatment of ... today announced its financial results for the second quarter ... 31, 2015. --> ... quarter of fiscal 2016, which ended December 31, 2015, ...
(Date:2/10/2016)... plc (NYSE: AGN ) a leading global pharmaceutical ... CEO and President, will be featured as the keynote ... Capital Markets Healthcare Conference on Tuesday, February 23, 2016 ... Hotel in New York, NY . ... accessed on Allergan,s Investor Relations web site at ...
Breaking Biology Technology:
(Date:2/10/2016)... India , February 10, 2016 /PRNewswire/ ... --> According to 2016 iris recognition ... identification iris recognition is more widely accepted ... available with both fingerprint and iris recognition ... the user to avoid purchasing two individual ...
(Date:2/9/2016)... -- Aware, Inc. (NASDAQ: AWRE ), a leading supplier of ... quarter and year ended December 31, 2015.  ... 2015 was $6.9 million, an increase of 61% compared to $4.3 ... fourth quarter of 2015 was $2.6 million compared to $0.2 million ... --> Higher revenue and operating income in the ...
(Date:2/9/2016)... Vigilant Solutions announces today that an agency used ... a lead in a difficult homicide case. The agency then ... the suspect vehicle. Due to the ongoing investigation, the agency ... at the agency,s request. --> ... was found deceased at an intersection here in the City. ...
Breaking Biology News(10 mins):